The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report 2025
Synopsis
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols and CSL Behring (CSL Limited), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Report Scope
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teijin Pharma
Shire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Bio Products Laboratory
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals
Segment by Type
Corticosteroid Therapy
IVIG Treatment
Plasma Exchange Therapy
Immunosuppressive Drug Therapy
Immunomodulator Therapy
Other
Segment by Application
Hospital
Specialist Neurology Clinic
Research and Academic Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols and CSL Behring (CSL Limited), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Report Scope
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teijin Pharma
Shire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Bio Products Laboratory
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals
Segment by Type
Corticosteroid Therapy
IVIG Treatment
Plasma Exchange Therapy
Immunosuppressive Drug Therapy
Immunomodulator Therapy
Other
Segment by Application
Hospital
Specialist Neurology Clinic
Research and Academic Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Corticosteroid Therapy
1.2.3 IVIG Treatment
1.2.4 Plasma Exchange Therapy
1.2.5 Immunosuppressive Drug Therapy
1.2.6 Immunomodulator Therapy
1.2.7 Other
1.3 Market by Application
1.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Specialist Neurology Clinic
1.3.4 Research and Academic Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2019-2030)
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Region
2.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Region (2019-2024)
2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Region (2025-2030)
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics
2.3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Trends
2.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
2.3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
2.3.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue
3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2019-2024)
3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue
3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio
3.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2023
3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Area Served
3.6 Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
3.7 Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Type
4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2019-2024)
4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2025-2030)
5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application
5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Application (2019-2024)
5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2019-2030)
6.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024)
6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2019-2030)
7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024)
7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2019-2030)
8.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2019-2030)
9.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024)
9.4 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2019-2030)
10.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teijin Pharma
11.1.1 Teijin Pharma Company Detail
11.1.2 Teijin Pharma Business Overview
11.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.1.5 Teijin Pharma Recent Development
11.2 Shire
11.2.1 Shire Company Detail
11.2.2 Shire Business Overview
11.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.2.5 Shire Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Detail
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.4.5 Octapharma Recent Development
11.5 Momenta Pharmaceuticals
11.5.1 Momenta Pharmaceuticals Company Detail
11.5.2 Momenta Pharmaceuticals Business Overview
11.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.5.5 Momenta Pharmaceuticals Recent Development
11.6 Mitsubishi Tanabe Pharma Corporation
11.6.1 Mitsubishi Tanabe Pharma Corporation Company Detail
11.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview
11.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development
11.7 Kedrion
11.7.1 Kedrion Company Detail
11.7.2 Kedrion Business Overview
11.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.7.5 Kedrion Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.8.5 Grifols Recent Development
11.9 CSL Behring (CSL Limited)
11.9.1 CSL Behring (CSL Limited) Company Detail
11.9.2 CSL Behring (CSL Limited) Business Overview
11.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.9.5 CSL Behring (CSL Limited) Recent Development
11.10 Bio Products Laboratory
11.10.1 Bio Products Laboratory Company Detail
11.10.2 Bio Products Laboratory Business Overview
11.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.10.5 Bio Products Laboratory Recent Development
11.11 Baxter
11.11.1 Baxter Company Detail
11.11.2 Baxter Business Overview
11.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.11.5 Baxter Recent Development
11.12 MedDay Pharmaceuticals
11.12.1 MedDay Pharmaceuticals Company Detail
11.12.2 MedDay Pharmaceuticals Business Overview
11.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.12.5 MedDay Pharmaceuticals Recent Development
11.13 GeNeuro Pharmaceuticals
11.13.1 GeNeuro Pharmaceuticals Company Detail
11.13.2 GeNeuro Pharmaceuticals Business Overview
11.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
11.13.5 GeNeuro Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Corticosteroid Therapy
Table 3. Key Players of IVIG Treatment
Table 4. Key Players of Plasma Exchange Therapy
Table 5. Key Players of Immunosuppressive Drug Therapy
Table 6. Key Players of Immunomodulator Therapy
Table 7. Key Players of Other
Table 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2019-2024)
Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2025-2030)
Table 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends
Table 15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
Table 16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
Table 17. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints
Table 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2019-2024)
Table 20. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2023)
Table 21. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
Table 25. Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2019-2024)
Table 29. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2025-2030)
Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2019-2024)
Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2025-2030)
Table 35. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2025-2030) & (US$ Million)
Table 50. Teijin Pharma Company Detail
Table 51. Teijin Pharma Business Overview
Table 52. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 53. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 54. Teijin Pharma Recent Development
Table 55. Shire Company Detail
Table 56. Shire Business Overview
Table 57. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 58. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 59. Shire Recent Development
Table 60. Pfizer Company Detail
Table 61. Pfizer Business Overview
Table 62. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 63. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 64. Pfizer Recent Development
Table 65. Octapharma Company Detail
Table 66. Octapharma Business Overview
Table 67. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 68. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 69. Octapharma Recent Development
Table 70. Momenta Pharmaceuticals Company Detail
Table 71. Momenta Pharmaceuticals Business Overview
Table 72. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 73. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 74. Momenta Pharmaceuticals Recent Development
Table 75. Mitsubishi Tanabe Pharma Corporation Company Detail
Table 76. Mitsubishi Tanabe Pharma Corporation Business Overview
Table 77. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 78. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 79. Mitsubishi Tanabe Pharma Corporation Recent Development
Table 80. Kedrion Company Detail
Table 81. Kedrion Business Overview
Table 82. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 83. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 84. Kedrion Recent Development
Table 85. Grifols Company Detail
Table 86. Grifols Business Overview
Table 87. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 88. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 89. Grifols Recent Development
Table 90. CSL Behring (CSL Limited) Company Detail
Table 91. CSL Behring (CSL Limited) Business Overview
Table 92. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 93. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 94. CSL Behring (CSL Limited) Recent Development
Table 95. Bio Products Laboratory Company Detail
Table 96. Bio Products Laboratory Business Overview
Table 97. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 98. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 99. Bio Products Laboratory Recent Development
Table 100. Baxter Company Detail
Table 101. Baxter Business Overview
Table 102. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 103. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 104. Baxter Recent Development
Table 105. MedDay Pharmaceuticals Company Detail
Table 106. MedDay Pharmaceuticals Business Overview
Table 107. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 108. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 109. MedDay Pharmaceuticals Recent Development
Table 110. GeNeuro Pharmaceuticals Company Detail
Table 111. GeNeuro Pharmaceuticals Business Overview
Table 112. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 113. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024) & (US$ Million)
Table 114. GeNeuro Pharmaceuticals Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2023 VS 2030
Figure 3. Corticosteroid Therapy Features
Figure 4. IVIG Treatment Features
Figure 5. Plasma Exchange Therapy Features
Figure 6. Immunosuppressive Drug Therapy Features
Figure 7. Immunomodulator Therapy Features
Figure 8. Other Features
Figure 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2023 VS 2030
Figure 11. Hospital Case Studies
Figure 12. Specialist Neurology Clinic Case Studies
Figure 13. Research and Academic Laboratories Case Studies
Figure 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered
Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region: 2023 VS 2030
Figure 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2023
Figure 19. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2023
Figure 21. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2019-2030)
Figure 23. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2019-2030)
Figure 27. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2019-2030)
Figure 35. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2019-2030)
Figure 43. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2019-2030)
Figure 47. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 50. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 51. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 52. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 53. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 54. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 55. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 56. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 57. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 58. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 59. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 60. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 61. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2019-2024)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
